15th November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Alembic Pharmaceuticals gets USFDA nod for Cyclophosphamide Capsules

Alembic Pharmaceuticals declared that they have received final approval from the US regulatory body for its ANDA (Abbreviated New Drug Application) for Cyclophosphamide Capsules, 25 mg, and 50 mg.

Aurobindo Pharma stock recovers 6% after a low hit following Director's arrest

On Monday, the Pharma firm’s stock recovered 6% from the low hit on November 10 which happened after the news of Director P Sarath Chandra Reddy’s arrest by the Enforcement Directorate came out. The company’s shares fell nearly 7 percent in early trade.

98 million people in India may have Type 2 Diabetes by 2030: Lancet's study

A study published in the ‘Lancet Diabetes & Endocrinology journal stated that nearly 98 million Indian people may have type 2 diabetes by the year 2030. It also mentioned that the amount of insulin needed to effectively treat type 2 diabetes will hike by more than 20% globally over the next 12 years.

DCGI's SEC to hold meeting on 'Five Arms' intranasal heterologous booster dose

The (SEC) Subject Matter Committee of the DCGI (Drugs Controller General of India) is going to meet on November 15 and conduct a discussion on Bharat Biotech International Ltd’s intranasal “Five Arms” booster dose – iNCOVACC.

Roche's Alzheimer's drug fails to achieve goal in long-awaited trial

Roche’s Alzheimer’s drug candidate failed to show the slowing down of the progression of Dementia in its two-drug trials. The firm’s setback left Biogen and Eisai as leaders in this race to launch a treatment for the memory-loss disease.

Satsuma Pharma's stocks crash after failure of migraine drug in late-stage trials

Satsuma Pharmaceuticals announced on Monday that its experimental drug candidate for the treatment of acute Migraine headaches failed to give positive results in the late-stage trial, dropping its shares 83% in premarket trade.

Are anti-diabetic drugs as the "Holy Grail" for Indian Pharma?

Anti-diabetic drugs are a major driver for Indian Pharma companies and it continues to push in the metabolic disorders arena. The surge in demand for anti-diabetic medications shows that there is a rise in the number of diabetic patients in the country and a shift of focus of the pharma industries towards new therapy areas.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?